GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop

Area of Science:

• Neuroscience
• Regenerative Medicine
• Clinical Neurology

Background:

• Glial cell line-derived neurotrophic factor (GDNF) has been investigated for neurodegenerative diseases, particularly Parkinson's disease (PD).
• GDNF promotes survival and regeneration of dopaminergic neurons, crucial for PD treatment.
• Previous clinical trials explored GDNF delivery via infusions or gene therapy.

Purpose of the Study:

• To critically appraise the existing research on GDNF for Parkinson's disease.
• To discuss and debate the future therapeutic potential of GDNF and related factors in PD.
• To provide recommendations for future clinical trial designs involving GDNF in PD.

Main Methods:

• A workshop was convened to discuss and debate the efficacy of GDNF in PD.
• Existing clinical trial data, including open-label and double-blind, placebo-controlled studies, were reviewed.
• Expert opinions and recommendations were synthesized from the workshop discussions.

Main Results:

• Initial studies suggested potential benefits of GDNF when delivered to the putamen.
• Subsequent double-blind, placebo-controlled trials, including one in 2019, did not meet their primary endpoints.
• Uncertainty remains regarding the therapeutic value of GDNF and related factors for PD.

Conclusions:

• The therapeutic merit of GDNF for Parkinson's disease requires further critical evaluation.
• Future trials should carefully consider trial design, including delivery methods and patient selection.
• Recommendations were made regarding the future use of GDNF and related neurotrophic factors in PD treatment strategies.